You are here:

nicotinic acid/laropiprant (Tredaptive)


The European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that the marketing, supply and authorisations of extended-release niacin/laropiprant medicines (Tredaptive®) be suspended across the EU. This follows an assessment of the available data related to safety concerns, and the conclusion by the Committee that the risks are greater than the benefits in adults with dyslipidaemia.
The SMC Advice has been removed from the website.

Drug Details

Drug Name: nicotinic acid/laropiprant (Tredaptive)
SMC Drug ID: 614/10
Manufacturer: MSD
Indication: dyslipidaemia
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Full submission
Status: Suspended
Date Advice Published: 10 May 2010

Extra Notes

The marketing authorisation for nicotinic acid/laporirant (Tredaptive) has been suspended.